SC
FULC icon

Stempoint Capital’s Fulcrum Therapeutics FULC Stock Holding History

Stempoint Capital’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-696,464
Closed -$4.32M – 58
2024
Q2 		$4.32M Buy
696,464
+289,356
+71% +$2.19M 1.27% 26
2024
Q1 		$3.84M Buy
407,108
+30,535
+8% +$273K 1.02% 28
2023
Q4 		$2.54M Buy
+376,573
New +$1.67M 0.68% 47

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Stempoint Capital's FULC Position: Q3 2024 in Review

Stempoint Capital sold out of Fulcrum Therapeutics (FULC) in Q3 2024, closing a stake of 696,464 shares — an estimated $4.32M sold.

Stempoint Capital first reported a position in FULC in Q4 2023 and held it in 3 quarters. The position peaked at $4.32M in Q2 2024. 130 funds tracked by Wall St. Rank hold FULC as of Q3 2024.

  • Stempoint Capital reported no remaining Fulcrum Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Stempoint Capital sold 696,464 Fulcrum Therapeutics shares in Q3 2024, an estimated $4.32M.
  • Stempoint Capital first reported a position in Fulcrum Therapeutics in Q4 2023 and held it in 3 quarters.
  • Stempoint Capital's Fulcrum Therapeutics position peaked at $4.32M in Q2 2024.
  • 130 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2024.

Based on Stempoint Capital's 13F filing for Q3 2024, filed 13 Nov 2024.